Figure 7.

SVR12 by treatment history and cirrhosis status in the BOSON trial, which compared sofosbuvir plus peginterferon/ribavirin (SOF + PEG/RBV) vs sofosbuvir plus ribavirin (SOF + RBV) in HCV genotype 3 patients and treatment-experienced cirrhotic patients with HCV genotype 2. Error bars show the 95% confidence intervals. SVR12, sustained virologic response at week 12. Adapted from Foster GR et al. Sofosbuvir + peginterferon/ribavirin for 12 weeks vs sofosbuvir + ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: the BOSON study [EASL abstract LO5]. J Hepatol. 2015;62(1)(suppl).³